With the current price of $1.61, the stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) concluded the trading session seeing its price drop by -0.44 points or at a loss of -21.46% compared to its previous day’s closing price of $2.05. About 13.468 million shares of the stock changed hands on the day. The trading volume of TXMD’s shares during the past session compares with the stock’s average daily trading volume of 5.225 million shares. On the other hand, a float of 237 million shares and a weekly performance of -17.44% make the stock worth to keep an eye on. Analysts are in agreement on an annual target price of $0 for TXMD’s share which suggests that the stock, price of which is currently buoying between $1.58 and $1.85, is prone to a loss of -100%. But still, there are some analysts recommending a price below the agreed average price and one of them has given a target price of $1.25 to the stock.
The latest data released on July 15, 2020 shows that the short float in the TherapeuticsMD, Inc.’s stock is trending upward as short interest in TXMD shares climbed up leaving more number of shares available to public for trading. Number of shares shorted in the TXMD is currently comprised of 35.01% of the float as the volume of shorted shares inclined by 106564 shares. Over the past two weeks, stock’s short interests weakened as number of shorted shares increased to 82.965 million shares from the previous figure of 82.858 million shares. Stock’s average intraday volume is now standing at 4.401 million shares which indicate that the days to cover the shorts are nearly 18.852688.
After concluding the day’s trading, price of TherapeuticsMD, Inc. (NASDAQ:TXMD) is down -$0.34 over the week and it is $0.14 above 20-day average price. The highest price touched by the stock on the day was lower than 52-week high price of $4.32 that was attained on 09/25/19.
The stock has traded as low as $0.85 in past 52-week, and its current price is 88.75% above from that 52-week low price mark recorded on 04/15/20, which is an indicator that could increase the investors’ motivation level in taking advantage of price surge the stock has currently been going through. Stock currently has its beta at 2.33. A beta value of more than 1 represents higher volatility of a stock than that of the market and for the reason investors closely watch the behavior of such stock.
Current indicators are pointing at 44.85 as 14-days RSI of TherapeuticsMD, Inc. This means that the TXMD is currently in a neutral territory and its share’s price movement is likely to be steady for a while. Similarly, the stochastic oscillator is indicating a momentum of 30.61%, implying stock’s share price is buoying in a neutral state.
Technical chart is showing 1st resistance point of $1.78 for the TXMD’s share while placing it at a 2nd resistance point of $1.95 to be settled at. But if the stock takes a plunge lower than the 1st support price of $1.51 then its market would become weakened. And that would likely sliding the stock price down to 2nd support price level of $1.41.
MACD oscillator is showing a reading of -0.05 for the stock which means that it is currently in the red zone. Any movement above or below the zero level of the indicator has always being noticed by the investors as it makes them compare the stock’s average measure in short-term with that in the long-term. An MACD evaluation of more than zero means that stock has a stronger short-term average than long-term average, which implies that stock’s price is likely to climb up. But an MACD below zero indicates weaker short-term average compare to the long-term average.
JP Morgan lowered its recommendation for TXMD stock from Overweight to Neutral in a review note dated May 19. The stock gets a Buy recommendation from analysts at Guggenheim who started covering the stock in their December 02 note to investors.H.C. Wainwright analysts started covering the stock with recommendation of Buy rating on October 17, while suggesting a price target of $7 to it.
The average rating of 2 for TXMD is placing the stock in bullish category at the moment. In a poll by Reuters including 9 analysts in it who kept tracking the TherapeuticsMD, Inc., 2 rated the stock as hold. Others were in different opinions for the TXMD. Out of remaining 7 analysts, 7 rated the stock as a buy or strong buy. 0 were in favor of a sell rating for the stock while advising investors to shun the stock if they already have any or otherwise not to buy it.
A quick look at other side of the picture shows that TXMD stock is lagging behind earnings per share estimates with a forward price-to-earnings ratio of 0.
Projection by Zacks Consensus Estimates suggests that TherapeuticsMD, Inc. (NASDAQ:TXMD) will see its current-quarter revenues drop by nearly -99.92% to be decreased to about $10.38 million. Full-year revenue of the company is however forecasted to be increased by nearly 20.93% to bring $60.04 million in revenues against last year revenue of $49.65 million. Earnings, after adjustments, are likely to fell by -26.09% to post an EPS of -$0.17, while estimate for company’s full year earnings is -$0.62 per share with a growth rate of -13.89%.